GDC-0919

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Solid Tumor

Phase 1

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

CompletedNCT02048709

Genentech, Inc.Solid Tumor

Start: 2014-04-30End: 2016-02-29Updated: 2017-02-06

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

CompletedNCT02471846

Genentech, Inc.Solid Tumor

Start: 2015-07-28End: 2019-10-02Updated: 2019-10-22

Related Papers

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal for ImmunoTherapy of Cancer2018-06-19149 citations

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2017-05-2028 citations

First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919.

Journal of Clinical Oncology2014-05-2015 citations

A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors

Journal for ImmunoTherapy of Cancer2014-01-0133 citations